

ห้องสมุดงานวิจัย สำนักงานคณะกรรมการวิจัยแห่งชาติ



E46986

PREPARATION OF CHITOSAN AND TRIMETHYLCHITOSAN (TMC)
PARTICLES FOR ORAL VACCINE DELIVERY

SUPAVADEE BOONTHA

A Thesis Submitted to the Graduate School of Naresuan University
in Partial Fulfillment of the Requirements
for the Doctor of Philosophy Degree
in Pharmaceutical Sciences (International Program)

May 2011

Copyright 2011 by Naresuan University

600246667



E46986

**PREPARATION OF CHITOSAN AND TRIMETHYLCHITOSAN (TMC)
PARTICLES FOR ORAL VACCINE DELIVERY**



SUPAFADEE BOONTHA

**A Thesis Submitted to the Graduate School of Naresuan University
in Partial Fulfillment of the Requirements
for the Doctor of Philosophy Degree
in Pharmaceutical Sciences (International Program)**

May 2011

Copyright 2011 by Naresuan University

This thesis entitled "Preparation of chitosan and trimethylchitosan (TMC) particles for oral vaccine delivery" submitted by Supavadee Boontha in partial fulfillment of the requirements for the Doctor of Philosophy in Pharmaceutical Sciences is hereby approved.

Tasana Pitaksuteepong.....Chair
(Associated Professor Tasana Pitaksuteepong, Ph.D.)

Neti Waranuch.....Committee
(Associated Professor Neti Waranuch, Ph.D.)

Assadang Polnok.....Committee
(Assistant Professor Assadang Polnok, Ph.D.)

Hans F. Junginger.....Committee
(Professor Hans F. Junginger, Ph.D.)

Anothai Tangsumranjit.....Committee
(Assistant Professor Anothai Tangsumranjit, Ph.D.)

Narong Sarisuta.....Committee
(Professor Narong Sarisuta, Ph.D.)

Sit Thirapakpoomanunt.....Committee
(Sit Thirapakpoomanunt)

Approved
Kanungnit Pupatwibul.....
(Assistant Professor Kanungnit Pupatwibul, Ph.D.)

Dean of Graduate School

May 2011

ACKNOWLEDGEMENT

Firstly, I would like to sincerely thank Associated Professor Dr. Tasana Pitaksuteepong, my advisor, for all of her invaluable guidance and support throughout my research. Without her thoughtful advice, this work would not have been possible. Her dedication to the success of her students is surpassed only by her kindness.

I am profoundly grateful to Professor Dr. Hans E. Junginger, for discussion and suggestions during the work and for reading manuscripts and the thesis. Additionally, thank are entended to Associated Professor Dr. Neti Waranuch, Assistant Professor Dr. Assadang Polnok and Assistant Professor Dr. Anothai Tangsumranjit for serving on my thesis committee and for all of their help with making this work the best that it can be. A special thank to Associated Professor Dr. Sakchai Wittaya-areekul who first established my research experience and persuaded me to persue Ph.D. study here.

I would like to thank the National Center for Genetic Engineering and Biotechnology (BIOTEC) for the research grant, the Strategic Scholarships Fellowships Frontier Research Networks of the Commission on Higher Education and Naresuan University for the Ph.D. scholarship. University of Payao, Payao is acknowledged for giving me the opportunity to study at the faculty of Pharmaceutical sciences, Naresuan University.

I am very grateful to Supaporn Tuanthai for doing many TMC synthesis and her technical support. Thanks to Prakaithip Kittikul for the SEM images. I would also like to thank all my co-workers espicially Worawon Boonyo, Supaporn Tuanthai, Sirikanya Suppracha, Nipaporn Thosuwan, and Pimolwan Atichartvanich, whose ability to provide constant support has reduced seemingly insurmountable problems to virtually nothing. Also, thank to fellow graduate students at lab room on fourth floor, who were not only colleagues but friends as well. They offered the daily motivation and shared so many special moments.

Finally and importantly, I would like to thank my parents and my sister for their unconditional support. Without their kindness support, my Ph.D. work would not have been finished.

Supavadee Boontha

Title	PREPARATION OF CHITOSAN AND TRIMETHYLCHITOSAN (TMC) PARTICLES FOR ORAL VACCINE DELIVERY
Author	Supavadee Boontha
Advisor	Associated Professor Tasana Pitaksuteepong, Ph.D.
Co-Advisor	Associated Professor Neti Waranuch, Ph.D. Assistant Professor Assadang Polnok, Ph.D. Professor Hans E. Junginger, Ph.D.
Academic Paper	Thesis Ph.D. in Pharmaceutical Sciences, Naresuan University, 2010
Keywords	Chitosan Trimethylchitosan Particles Oral vaccine delivery

ABSTRACT

E46986

The principal aim of this thesis was to develop chitosan and trimethylchitosan (TMC) particles for oral Japanese encephalitis virus (JEV) delivery. In this study, three types of chitosan having different molecular weight (MW) and their respective TMC synthesized with a degree of quaternization (DQ) of 20%, 40% and 60% were used to prepare particles by ionic gelation method. The study started with preparation of chitosan and TMC particles having the potential for oral vaccine delivery using ovalbumin (OVA) as a model antigen. This step included the investigation of the effect of types of polymers (i.e. chitosan and TMC), the MW of chitosan and the DQ of TMC on the formation of particles and the characteristics of the particles obtained by optimizing the amount of tripolyphosphate (TPP) added. The chitosan and TMC particles prepared were tested for their potential to enhance immune response to OVA following oral immunization. Subsequently, the best formulations were selected and tested for the ability to induce immune response to JEV. The results showed that the amount of TPP added has an effect on the formation of chitosan and TMC particles. The formation of chitosan particles required higher amount of TPP than that of TMC particles. Using the same amount of TPP, the MW of chitosan did not have an effect on the formation of particles whereas the DQ of TMC did have. TMC particles with a DQ of 60% could not be prepared because of its high water solubility. Based on theirs

high loading capacity of OVA and slow release profile, particles prepared using chitosan with low and medium MW and their respective TMC with a DQ of 40% which was shown to be the most potent in the parallel study via nasal route were selected to test for the ability to enhance immune response to OVA. Chitosan was likely to enhance higher immune responses than TMC. Thus, only chitosans with three different MWs were selected to test for the ability to initiate immune response to JEV. It was found that JEV encapsulated in all types of chitosan particles could induce the JEV-neutralizing antibodies levels higher than the minimal requested level ($>1:10$) by World Health Organization (WHO) following oral immunization in Swiss albino mice. However, the JEV-neutralizing antibodies initiated by particles prepared using three types of chitosan were not significantly different. In conclusion, the results of this thesis demonstrate that chitosan particles as adjuvant have the feasibility for oral JEV immunization and the MW of chitosan appeared to have no effect on the ability to elicit protective neutralizing antibodies to JEV in Swiss albino mice after oral immunization. Interestingly, although the differences were not statistically significant, free JEV (i.e. JEV in sterile water for injection (SWFI)) seemed to be better in the initiation of immune responses to JEV compared with particles-encapsulated JEV. Thus, the further work on the enhanced of immune initiation against JEV encapsulated in any delivery systems is necessary to be carefully considered.

LIST OF CONTENTS

Chapter	Page
I INTRODUCTION.....	1
II REVIEW OF RELATED LITERATURE AND RESEARCH.....	6
The Japanese encephalitis virus.....	6
Oral vaccination.....	9
Particulate system as an adjuvant for oral vaccination.....	10
Chitosan and trimethylchitosan (TMC).....	11
III RESEARCH METHODOLOGY.....	24
Materials	24
Synthesis and characterization of trimethylchitosan (TMC).....	25
Preparation of chitosan and TMC particles having the potential for oral vaccine delivery using ovalbumin (OVA) as a model antigen	27
Evaluation of the potential of the best formulation for enhancing immune responses against JEV after oral immunization.....	34
Statistical analysis.....	37
IV RESULTS AND DISCUSSION.....	38
Preparation of chitosan and TMC particles having the potential for oral vaccine delivery using ovalbumin (OVA) as a model antigen	38
Evaluation of the potential of the best formulation for enhancing immune responses against JEV after oral immunization.....	69
V CONCLUSIONS.....	80

LIST OF CONTENTS (CONT.)

Chapter	Page
REFERENCES.....	85
BIOGRAPHY.....	96

LIST OF TABLES

Table	Page
1 Composition, storage, dose and administration of inactivated mouse brain-derived Japanese encephalitis vaccine (JE-MB) and inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC).....	8
2 Oral vaccines currently in the market or at different stages of development.....	9
3 The characteristics of the starting chitosan and their respective synthesized TMC derivative.....	26
4 Effect of the amount of TPP added on particle formation.....	41
5 The percentage yield of particles prepared from the starting chitosan and their respective synthesized TMC derivatives (n=2).....	47
6 Characteristics of OVA-loaded particles.....	65
7 Characteristics of JEV-loaded particles.....	74

LIST OF FIGURES

Figures	Page
1 Scheme of the thesis conceptual framework	5
2 Japanese encephalitis virus	6
3 The transmission cycle of Japanese encephalitis virus.....	7
4 The trend of exporting frozen shrimps in Thailand.....	12
5 Scheme of synthesis reactions for trimethylchitosan (TMC).....	13
6 Schematic representation of the induction of immune responses at the gut-associated lymphoid tissues (GALT).....	21
7 Relationship of log[n] and log [MW] for TMC (a) and chitosan (b) samples.....	42
8 Effect of the amount of TPP added on the size of particles prepared from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40 derivatives (n=2).....	43
9 Effect of the amount of TPP added on the surface charge of particles prepared from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40 derivatives (n=2).....	44
10 Effect of pH on zeta potential of chitosan solutions having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40. The zeta potential was expressed as mean \pm S.D. (n=3).....	45
11 Scanning Electron Microscope (SEM) images of chitosan particles (a) and TMC particles (b).....	46
12 Size of OVA-loaded particles prepared by adsorption method from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40 derivatives (n=3)..	49

LIST OF FIGURES (CONT.)

Figures	Page
13 Zeta potential of OVA-loaded particles prepared by adsorption method from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40 derivatives (n=3).....	50
14 Loading efficiency (%LE) (a) and loading capacity (%LC) (b) of OVA on particles prepared by adsorption method from chitosan having low, medium and high MW and their respective synthesized TMC-20 and TMC-40 derivatives. The LE and LC were expressed as mean \pm S.D. (n=3).....	52
15 Release profiles of OVA from particles prepared by adsorption method from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-20 and TMC-40 derivatives. The amount of OVA released was expressed as mean \pm S.D. (n=3).....	54
16 Size of OVA-loaded particles prepared by encapsulation method from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-40 derivatives (n=3).....	57
17 Zeta Zeta potential of OVA-loaded particles prepared by encapsulation method from chitosan having low (a), medium (b) and high (c) MW and their respective synthesized TMC-40 derivatives (n=3)	58
18 Loading efficiency (%LE) (a) and loading capacity (%LC) (b) of OVA in particles prepared by encapsulation method from chitosan having low, medium and high MW and their synthesized TMC-40 derivatives (n=3). Significant differences were designated as * ($p < 0.05$).....	60

LIST OF FIGURES (CONT.)

Figures	Page
19 Release profiles of OVA from particles prepared by encapsulation method from chitosan having low (a), medium (b) and high (c) MW and their synthesized TMC-40 derivatives (n=3).....	62
20 Serum IgG antibodies obtained from mice following oral immunization with OVA in PBS, pH 7.4 and in particles prepared from Chi-L, Chi-M, TMC-L-40 and TMC-M-40. OVA in alum administered subcutaneously was used as a positive control. IgG antibodies at day 13 and day 21 were obtained from pooled serum, while IgG antibodies at day 28 were obtained from individual sera. IgG antibodies at day 0 were not detectable. The IgG antibodies at day 13 and day 21 were expressed as mean \pm S.E.M (n=3) while the IgG antibodies at day 28 were expressed as mean \pm S.E.M (n=7-8). Significant differences with the control groups were designated as * ($p < 0.05$).....	66
21 Secretory IgA antibodies obtained from mice following oral immunization with OVA in PBS, pH 7.4 and in particles prepared from Chi-L, Chi-M, TMC-L-40 and TMC-M-40. OVA in alum administrated subcutaneously was used as a positive control. sIgA antibodies were obtained from individual fecal extracts. sIgA antibodies at day 0 were not detectable. The sIgA antibodies were expressed as mean \pm S.E.M (n=7-8). Significant differences with the control groups were designated as * ($p < 0.05$).....	68
22 Size (a) and zeta potential (b) of the empty and JEV-loaded particles prepared from chitosan having low (Chi-L), medium (Chi-M) and high (Chi-H) MW (n=3). Significant differences were designated as * ($p < 0.05$).....	70

LIST OF FIGURES (CONT.)

Figures	Page
23 Loading efficiency (LE) (a) and loading capacity (LC) (b) of JEV-loaded particles prepared from chitosan having low (Chi-L), medium (Chi-M) and high (Chi-H) MW (n=3).....	71
24 Release profiles of JEV from the particles prepared from chitosan having low (Chi-L), medium (Chi-M) and high (Chi-H) M (n=3)...	72
25 Body weight of mice after oral immunization with JEV in different formulations.....	75
26 The PRNT ₅₀ of JEV-neutralizing antibodies obtained from the sera of mice following oral immunization with JEV in different formulations. PRNT ₅₀ at day 37 were obtained from individual sera. Each circle represents the result of individual sera samples and the horizontal bar represents the GMT of the group. The black arrow indicates a protective level of PRNT ₅₀ ≥ 1:10, accepted by the WHO, as an immunological correlate of protection from JE in human.....	76
27 Seroconversion rates of mice following oral immunization with JEV in different formulations. The number above the bars presents the number of sera giving the minimum protective level of PRNT ₅₀ ≥ 1:10 per number of animals tested.....	77
28 Proposal of the DC signal on the surface JEV virions was shielded by chitosan particles matrixs.....	79

ABBREVIATIONS

APCs	=	Antigen presenting cells
BSA	=	Bovine serum albumin
DCs	=	Dendritic cells
DD	=	Degree of deacetylation
DQ	=	Degree of quaternization
DT	=	Diphtheria toxoid
ELISA	=	Enzyme-Linked Immunosorbent Assay
FAE	=	Follicle-associated epithelium
FBS	=	Fetal bovine serum
g	=	Gram(s)
GALT	=	Gut-associated lymphoid tissue
GMT	=	Geometric mean titers
GPC	=	Gel permeation chromatography
GRAS	=	Generally Recognized As Safe
h	=	Hour(s)
HRP	=	Horseradish peroxidase
IgA	=	Immunoglobulin A
IgG	=	Immunoglobulin G
JEV	=	Japanese encephalitis virus
LC	=	Loading capacity
LE	=	Loading efficiency
M-cells	=	Microfold cells
MEM	=	Minimum essential medium
min	=	Minute(s)
MW	=	Molecular weight
NMP	=	N-methyl-2-pyrrolidone
NMR	=	Nuclear magnetic resonance

ABBREVIATIONS (CONT.)

OVA	=	Ovalbumin
PBS	=	Phosphate buffered saline solution
PBST	=	Tween 20 in phosphate buffered saline solution
PCS	=	Photon correlation spectroscopy
PDI	=	Polydispersity index
PRNT	=	Plaque reduction neutralization test
SCRs	=	Seroconversion rates
SEM	=	Scanning electron microscopy
sIgA	=	Secretory immunoglobulin A
SWFI	=	Sterile water for injection
T20	=	Tween 20
TPP	=	Sodium tripolyphosphate
TMC	=	Trimethylchitosan
TMB	=	3, 3', 5, 5' – tetramethylbenzidine
TT	=	Tetanus toxoid
WHO	=	World health organization
ZO-1	=	Zonula occludens 1